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Abstract
Epidemiological studies have reported a greater reduction in cardiovascular risk and metabolic disorders associated with diets rich in poly-
phenols. The antioxidant effects of polyphenols are attributed to the regulation of redox enzymes by reducing reactive oxygen species
production from mitochondria, NADPH oxidases and uncoupled endothelial NO synthase in addition to also up-regulating multiple anti-
oxidant enzymes. Although data supporting the effects of polyphenols in reducing oxidative stress are promising, several studies have
suggested additional mechanisms in the health benefits of polyphenols. Polyphenols from red wine increase endothelial NO production
leading to endothelium-dependent relaxation in conditions such as hypertension, stroke or the metabolic syndrome. Numerous molecules
contained in fruits and vegetables can activate sirtuins to increase lifespan and silence metabolic and physiological disturbances associated
with endothelial NO dysfunction. Although intracellular pathways involved in the endothelial effects of polyphenols are partially described,
the molecular targets of these polyphenols are not completely elucidated. We review the novel aspects of polyphenols on several targets
that could trigger the health benefits of polyphenols in conditions such as metabolic and cardiovascular disturbances.
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Polyphenols are found mainly in plant-derived foods and
beverages, and provide the tastes and colour of plant foods
while also participating in plant defensive responses against
stress due to UV radiation, pathogens and physical damage.
There are a number of excellent reviews dealing with their
protective effect against cancers, cardiovascular, metabolic(1)
and neurodegenerative diseases(2). The structures of polyphe-
nols vary from a simple phenol core to complex molecules
with a high degree of polymerisation. This family can be
divided into simple phenols, flavonoids and non-flavonoids
such as stilbene (resveratrol), saponin, curcumin and tannins.
Flavonoids can be subdivided according to their substituents
into flavanols (catechin and epicatechin), flavonols (quercetin,
myricetin and kaempferol), anthocyanidins (cyanidin and
delphinidin), flavones (apigenin and diosmin), flavanones
(naringenin and hesperetin) and chalcones (phloretin).
Dietary intake of polyphenols is highly variable. In the
USA, the intake in 1976 was estimated at 1 g of glycosylated
flavonoids per d(3). A Dutch study in 1987–88 established
lower amounts of flavanols and flavones of approximately
23 mg/d(4), but of the aglycone forms. In a cohort of US
women, the baseline mean intake of flavonols and flavone
was 21·2 mg/d, with quercetin (15·4 mg/d) being the major
contributor(5). The daily intake of anthocyanins in the USA is
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estimated to be 12·5 mg/d per person, with delphinidin contri-
buting approximately 21 % of the total anthocyanin intake(6).
An accurate estimate of dietary intake of polyphenols is
difficult to achieve because of the poor characterisation of
polyphenols in foods and the great variability of polyphenol
content within foods(7). The cardiovascular effects of polyphe-
nols have mostly been studied using extracts of polyphenols
in foods and drinks. Several other studies have used purified
resveratrol, quercetin and delphinidin to examine the cardio-
vascular effects of these components of polyphenols.
We summarise the cardiovascular effects and the mechan-
isms implicated in the health benefits associated with resvera-
trol, quercetin and delphinidin, by comparing their in vitro
effects on isolated cell systems and their in vivo repercussions
related to their absorption and bioavailability. It should be
noted that most in vitro studies have shown health benefits
at high concentrations (1–100mm), with plasma concen-
trations of polyphenols being approximately 1–20 nM(8).
Thus, despite their high absorption, bioavailability is low in
humans and precautions concerning the conclusions of
published studies are warranted.
Endothelial cells and the regulation of vascular
homeostasis
Endothelial cells of healthy blood vessels form a monolayer
at the luminal surface to provide chemically mediated control
of vascular homeostasis. Due to their strategic localisation,
these cells prevent the contact of circulating blood with the
underlying prothrombotic arterial wall. Endothelial cells play
a critical role in the control of vascular tone via the release
of relaxing factors such as NO, endothelium-derived hyper-
polarising factor (EDHF) and PGI2. The gaseous molecule
NO is generated from L-arginine by the enzyme endothelial
NO synthase (eNOS) and diffuses towards the underlying
vascular smooth muscle cell layer to dilate blood vessels in
a cyclic guanylyl monophosphate-dependent manner (Fig. 1).
NO can also diffuse towards the lumen to prevent platelet
adhesion and activation, and also monocyte adhesion.
In addition, NO prevents the expression of prothrombotic
and proatherosclerotic mediators including tissue factor, the
physiological activator of the coagulation cascade, adhesion
molecules, chemoattractant factors and the oxidation of
LDL (Fig. 1). A prominent role exists for EDHF in the control
of resistance artery tone by hyperpolarising vascular smooth
muscle. PGI2, generated by the arachidonic acid cascade via
cyclo-oxygenases (COX), activates the cyclic AMP pathway
during its vasodilator activity. The endothelial formation of
vasoprotective factors can be increased within seconds by
several stimuli including neurohumoral substances, products
released during the degranulation of activated platelets or
during the coagulation cascade, and by shear stress at the
endothelial cell surface (Figs. 1 and 2)(9). Many CVD such as
hypertension, hypercholesterolaemia and the metabolic
syndrome are characterised by an endothelial dysfunction
as indicated by reduced endothelium-dependent vasodi-
latation subsequent to a reduced bioavailability of NO. In
addition, ageing in humans and animal models is also associ-
ated with a progressive decline of endothelium-dependent
vasodilatation(10).
Endothelial dysfunction is often associated with pro-
nounced oxidative stress that is due, at least in part, to an
increased expression of NADPH oxidase, an enzyme generat-
ing superoxide anions in the arterial wall(11–13). Superoxide
anions react with NO to reduce its bioavailability and,
hence, vascular protective effects. Endothelial dysfunction is
frequently associated with the emergence of endothelium-
dependent contractile responses involving the unopposed
contractile actions of endothelin and vasoconstrictor factors
acting on thromboxane receptors(14).
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Fig. 1. Endothelium-derived NO contributes to the regulation of vascular homeostasis. In healthy blood vessels, endothelial cells release NO, which is produced
from L-arginine by endothelial NO synthase (eNOS). NO diffuses towards the underlying vascular smooth muscle to reduce vascular tone and keep smooth
muscle cells in a non-migratory and non-proliferative state. NO can also diffuse towards the lumen where at the surface of endothelial cells, it prevents platelet
adhesion and aggregation, and adhesion of monocytes. In addition, NO is also a potent inhibitor of the expression of several proatherothrombotic molecules such
as tissue factor, chemoattractant molecules such as monocyte chemoattractant protein-1, and adhesion molecules such as vascular cell adhesion molecule-1.
Moreover, NO retards the oxidation of LDL, a key step in the development of atherosclerosis. (A colour version of this figure can be found online at
http://www.journals.cambridge.org/bjn)
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Diets such as the Mediterranean diet are associated with
improved cardiovascular health(15), which may be related to
the high intake of polyphenol-rich beverages and foods, and
fruit and vegetables. The intake of polyphenol-rich sources
such as red wine, cocoa, green tea and berries also improves
cardiovascular health(16,17). The beneficial effects of polyphe-
nols on the cardiovascular system have been attributed to
mechanisms such as improved lipid profiles, anti-atherosclero-
tic, anti-hypertensive and anti-inflammatory effects, and direct
actions on endothelial cells (Fig. 2).
Vascular protection by extracts of polyphenols
That polyphenols cause endothelium-dependent relaxations
was first observed by Fitzpatrick et al.(18), where some
wines, grape juices and grape skin extracts caused endo-
thelium-dependent relaxations in aortic rings. Other studies
confirmed that polyphenol-rich sources such as extracts
from red wines, green and black tea, and several plants
caused endothelium-dependent relaxations in large arteries,
arterioles and veins that were prevented by competitive
inhibitors of eNOS and guanylyl cyclase(18,19). Direct proof
that polyphenols (1mg/ml) stimulate endothelial formation
of NO was obtained using electron paramagnetic resonance
spectroscopy using rat aortic rings and cultured endothelial
cells(20). However, in porcine coronary arteries, red wine
extract-induced relaxation was only partially prevented by
a competitive inhibitor of eNOS but abolished by the
addition of the combination charybdotoxin plus apamin, two
inhibitors of the EDHF-mediated relaxation, indicating the
involvement of both NO and EDHF(21). The endothelium-
dependent relaxation induced by red wine polyphenols is
observed at concentrations of 3mg/ml (or greater) in porcine
coronary artery rings(21). Although the concentration of red
wine polyphenols in the blood after the intake of red wine
remains unknown, estimates are that an intake of 100 ml of
red wine by healthy volunteers increases plasma concen-
trations of polyphenolic monomers to 2·5mg/ml(22). Thus,
the stimulatory effect of red wine polyphenols on NO levels
is observed at plasma concentrations likely to be achieved
with the moderate consumption of red wine.
The signal transduction pathway mediating the stimulatory
effect of polyphenols on eNOS suggests a key role of an
intracellular redox-sensitive mechanism(23). Thus, vasodilation
to red wine polyphenols, purple grape juice and grape skin
extracts are reduced by membrane-permeant analogues of
superoxide dismutase (SOD) and also to some extent by a
membrane-permeant analogue of catalase(24). Exposure of
cultured endothelial cells to polyphenols increased the intra-
cellular formation of reactive oxygen species (ROS)(21). ROS
can trigger the activation of sarcoma oncogene homolog
(Src) kinase by phosphorylation, which subsequently leads
to a phosphatidylinositol-3-kinase-dependent activation of
Akt by phosphorylation, which ultimately causes the phos-
phorylation of eNOS at Ser1177 to increase its activity in
response to polyphenols(21,25). Changes in Ca signalling and
oestrogen receptor (ER) function also contribute to eNOS acti-
vation caused by some polyphenols(26).
Polyphenol extracts reduce CVD
Polyphenols prevent and/or improve endothelial dysfunction
and reduce blood pressure in spontaneously hypertensive
rats (SHR)(27,28), and in deoxycorticosterone acetate salt(29),
the Nv-nitro-L-arginine(30) and angiotensin II(31) hypertension
models. In the latter case, ingestion of 150 mg/kg per d of a
red wine polyphenol extract in the drinking-water reduced
hypertension induced by angiotensin II in rats (0·4 mg/kg
per d for 28 d)(31). Angiotensin II-induced hypertension was
associated with blunted endothelium-dependent vasodilation
that was reversed by the ingestion of red wine polyphenols.
Moreover, angiotensin II-induced hypertension also increased
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Fig. 2. Endothelial formation of NO can be increased within seconds in response to numerous physiological activators such as neurohumoral substances, platelet-
derived products, products generated by the coagulation cascade, growth factors and shear stress induced by the flowing blood on the endothelial surface. In
addition, the endothelial formation of NO can also be stimulated in response to several nutritional-derived products including cocoa, berry polyphenols, red wine
polyphenols and green tea polyphenols. eNOS, endothelial NO synthase; ACh, acetylcholine; 5-HT, serotonin; VEGF, vascular endothelial growth factor; PDGF,
platelet-derived growth factor. (A colour version of this figure can be found online at http://www.journals.cambridge.org/bjn)
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oxidative stress due to the increased formation of ROS in the
arterial wall through the up-regulation of NADPH oxidase via
angiotensin type 1 receptors(12,13,31,32). Polyphenol-rich red
wine extracts abrogate the angiotensin II-stimulated up-
regulation of several NADPH oxidase subunits including Nox
1 and p22phox and the associated oxidative stress(31), probably
due to the inhibition of the angiotensin II-induced exp-
ression of NADPH oxidase by preventing angiotensin type 1
receptor expression(33). Polyphenols also exert antioxidant
activities in endothelial cells not only by reducing NADPH
oxidase expression but also reducing its activity, and
increasing the expression of antioxidant enzymes such as
catalase(34). Angiotensin II-induced endothelial dysfunction
includes endothelium-dependent contractile responses to
acetylcholine(35), which involves COX-dependent formation of
endothelium-derived contracting factors that act on thrombox-
ane receptors located on vascular smooth muscle cells. Both
the angiotensin II-induced vascular expression of COX and
the increased endothelium-derived contracting factors are sig-
nificantly reduced by red wine polyphenols(35). Thus, polyphe-
nols prevent ROS-mediated degradation of NO, and blunt
vasoconstrictor and pro-inflammatory responses (Fig. 3).
Polyphenol-rich products increase basal flow-mediated
dilation in healthy subjects at relatively low doses such as
those achieved after the intake of two glasses of red wine(36)
or 2 weeks of daily consumption of flavonoid-rich dark choco-
late bars (46 g)(37). Similar beneficial effects of polyphenol-rich
products on flow-mediated dilation occur in patients with cor-
onary artery disease after consumption of black tea(38), a green
tea extract(39) or a red grape extract(40). Systolic blood pressure
is improved in hypertensive patients by daily ingestion of
polyphenol-rich products such as a piece of a sixteen-piece
dark chocolate bar(41), two glasses of purple grape juice(42)
or 50 ml of pomegranate juice(43).
Resveratrol
Resveratrol is a stilbene identified in 1940 as a component of
Polygonum cuspidatum (Japanese knotweed) used to treat
hyperlipidaemic diseases. This polyphenol phytoalexin is
also present in several plant species, including white hellebore
(Veratrum grandiflorum O. Loes), grapes, peanuts and mul-
berries(44–46). Many of the cardioprotective effects of red
wine could be attributed to resveratrol, and recent studies
extend the benefits of resveratrol to the prevention or
retardation of cancer(45) and also to increasing the lifespan
of various organisms from yeast to vertebrates(44).
As a polyphenolic compound, resveratrol is an efficient
scavenger of hydroxyl, superoxide and metal-induced
radicals(45,47). However, the direct antioxidant effects of resver-
atrol are weaker than those of ascorbate and cysteine(45). The
protective effects of resveratrol against oxidative injury are
probably attributed to the up-regulation of the endogenous
cellular antioxidant system rather than to its direct ROS-
scavenging activity.
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Fig. 3. Potential mechanism(s) in the cardiovascular and metabolic effects of polyphenols. Polyphenols interact with oestrogen receptor a (ERa) to activate the
sirtuin-1 (SIRT1)–AMP-activated protein kinase (AMPK) network. Stimulation of SIRT1 and AMPK results in the activation of PPARg coactivator 1 a (PGC-1a),
placing mitochondria at the epicentre of targets for polyphenols in CVD and metabolic disorders. (A colour version of this figure can be found online at
http://www.journals.cambridge.org/bjn)
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Resveratrol and oxidative stress
Resveratrol increases the expression/activity of SOD, catalase
and glutathione peroxidase (GPx) in cardiac H9C2 cells(48)
and aortic smooth muscle cells(47,49). Another study, however,
found no changes in the protein levels of SOD1 or SOD2 but
an up-regulation of GPx1 and catalase in aortic segments or
cultured aortic smooth muscle(50). In a hamster model of
dilated cardiomyopathy, treatment with resveratrol increases
SOD2 levels, suppresses fibrosis, preserves cardiac function
and significantly improves survival(51). Treating hypercholes-
terolaemic, atherosclerosis-prone apoE-knockout (KO) mice
(as a model of oxidative stress) with resveratrol (30–100 mg/
kg per d for 7 d) leads to the up-regulation of SOD1, SOD2,
SOD3, GPx1 and catalase in the heart(51). The expression of
these enzymes is also increased by resveratrol in cultured
human endothelial cells(52,53).
The antioxidant transcription factor nuclear factor erythroid
2-related factor-2 (Nrf2) is a recently identified target of resver-
atrol(54,55). In cultured coronary arterial endothelial cells,
resveratrol increases the transcriptional activity of Nrf2 and
up-regulates the expression of Nrf2 target genes NAD(P)H:
quinone oxidoreductase 1, g-glutamylcysteine synthetase
(glutamate cysteine ligase catalytic subunit, GCLC) and
haem oxygenase-1(55). All these enzymes, together with
thioredoxin-1(56), could well contribute to the antioxidant
actions of resveratrol.
NADPH oxidases (NOX) are major sources of ROS in
the cardiovascular system(57,58). Resveratrol reduces the
expression of Nox2 and Nox4 in the heart of apoE-KO
mice(52) and also prevents Nox2 expression in the aorta of
diabetic mice(59). In human umbilical vein endothelial cells
(HUVEC) and HUVEC-derived EA.hy 926 endothelial cells,
resveratrol decreases the expression of Nox4(53), the most pre-
dominant Nox isoform in these cell types(60). Small-interfering
RNA (siRNA)-mediated knockdown of sirtuin 1 (SIRT1) has no
effect on the Nox4 down-regulation by resveratrol, indicating
that the effect of resveratrol on Nox4 is likely to be SIRT1-
independent(52).
Resveratrol and endothelial NO synthase uncoupling
Uncoupling of eNOS switches it from a NO-producing enzyme
to a superoxide-generating molecule. The major cause
of eNOS uncoupling under pathological conditions is a
deficiency of the eNOS cofactor tetrahydrobiopterin
(BH4)
(61,62). Tissue levels of BH4 are a balance of its biosyn-
thesis and degradation/oxidation: synthesis of BH4 from GTP
via a de novo pathway, with GTP cyclohydrolase 1 as the
rate-limiting enzyme, while rapid oxidation by peroxynitrite
makes the cofactor unavailable for eNOS generation of NO.
Untreated apoE-KO mice show increased oxidation of
BH4
(63) and significant ROS production in their aorta(63,64)
and heart(52). Both aortic(63,64) and cardiac(52) superoxide pro-
duction are reduced by the NOS inhibitor L-NG-nitroarginine
methyl ester (L-NAME), indicating that eNOS is in an
uncoupled state and that it produces ROS in this pathological
model. Resveratrol treatment enhances the expression of GTP
cyclohydrolase 1 and BH4 biosynthesis. In addition, resvera-
trol decreases the cardiac content of superoxide and peroxyni-
trite, and thereby decreases BH4 oxidation
(52). As a result, the
cardiac levels of BH4 are increased by resveratrol. Cardiac
superoxide production in resveratrol-treated mice is markedly
reduced to a level that cannot be lowered any further by L-
NAME(52), suggesting that eNOS no longer produces superox-
ide in resveratrol-treated apoE-KO mice, i.e. resveratrol
reverses eNOS uncoupling. The expression of GTP cyclohy-
drolase 1 in cultured human endothelial cells is increased by
resveratrol. This up-regulation is reduced by the SIRT1 inhibi-
tor sirtinol or by siRNA-mediated SIRT1 knockdown, indicat-
ing SIRT1-dependent mechanisms(52).
Resveratrol and vasodilation
Resveratrol causes vasodilation by releasing NO from
endothelial cells(65) and/or improving NO bioavailability(59).
Resveratrol increases endothelial eNOS mRNA(66) and pro-
tein(67) expressions, and causes rapid phosphorylation of
eNOS at Ser1177 (the activator site of this enzyme), and
thereby increasing eNOS enzymatic activity(68). In parallel,
resveratrol improves NO bioavailability by decreasing oxi-
dative stress per se (69). These actions combine to stimulate
cyclic guanylyl monophosphate formation, protein kinase G
activation and vasodilation(70). Voltage-gated Kþ channels,
large Ca2þ-activated-Kþ channels or voltage-gated Ca2þ
channels(71) mediate the endothelium-independent vasodilata-
tion caused by resveratrol. The vasodilator properties of
resveratrol offer cardiovascular and vascular protection in
several models of CVD.
Resveratrol and vasoconstriction
The endothelium also releases vasoconstrictor and mitogenic
substances such as endothelin-1, which under pathophysi-
ological conditions, counteracts the protective effects of
vasodilator products from endothelial cells. Resveratrol is
able to reduce endothelial mRNA expression and secretion
of endothelin-1(66), inhibit H2O2-induced endothelin-1
expression in human vascular smooth muscle cells(72) and
reduce endothelin-1 expression in the ischaemia–reperfused
heart(73).
The renin–angiotensin system regulates blood pressure via
the release of angiotensin II that interacts with angiotensin
type 1 receptors to evoke vasoconstriction(74). Resveratrol sup-
presses the mRNA and protein expressions of angiotensin
type 1 receptors in intact mice and also in isolated vascular
smooth muscle cells(33). Resveratrol also possesses a potent
in vitro angiotensin-converting enzyme (ACE) inhibitory
activity(75), which can partially account for resveratrol-induced
blood pressure-lowering effects in various animal models of
hypertension.
Resveratrol and inflammation
Resveratrol has in vitro and in vivo anti-inflammatory effects.
Resveratrol treatment decreases the overexpression of
R. Andriantsitohaina et al.1536
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114512003406
Downloaded from https://www.cambridge.org/core. IP address: 130.79.37.237, on 12 Jun 2018 at 06:59:22, subject to the Cambridge Core terms of use, available at
adhesion molecules (vascular cell adhesion molecule-1 and
intercellular adhesion molecule-1) by inhibiting the NF-kB
pathway in TNFa-activated endothelial cells(76). In intact
animal studies, resveratrol inhibits the angiotensin II-induced
adhesion of leucocytes to arterioles, partially by reducing
cellular adhesion molecule expression and circulating levels
of monocyte chemoattractant protein-1 and macrophage
inflammatory protein-1a(77). These effects may partially con-
tribute to the cardiovascular protective activity of resveratrol,
especially during the early phase of the atherosclerotic
process.
Resveratrol probably improves the pro-inflammatory profile
in human obesity by decreasing pro-inflammatory cytokine
secretion and increasing adiponectin release from human adi-
pose tissue(78). Resveratrol modulates adipokine expression
and improves insulin sensitivity in murine adipocytes, where
resveratrol treatment reduces the levels of pro-inflammatory
cytokines and adipokines (TNFa, IL-6 and resistin), and
increases adiponectin and PPARg expression and the Ser/Thr
phosphorylation state of insulin receptor substrate-1(79). In
addition, resveratrol also normalises the levels of pro-
inflammatory cytokines (IL-6 and TNF-a) and COX-2
expression by decreasing NF-kB activation in diabetic rats(80).
Resveratrol and platelet function
Resveratrol alters several functions of platelets: adhesion,
activation and aggregation of platelets, and thrombus for-
mation(81). Since tissue factor is the major determinant for
the extrinsic coagulation pathway, decreases in tissue factor
expression can reduce thrombosis risk. Resveratrol attenuates
an agonist-induced increase in tissue factor mRNA in endo-
thelial and mononuclear cells, resulting from the inhibition
of IkBa (inhibitor of kappa B) degradation, thus decreasing
the DNA-binding occupancy by the transcription factor
c-Rel/p65(82). Additionally, resveratrol inhibits platelet aggre-
gation induced by collagen, thrombin, ADP or arachidonic
acid(83). Resveratrol inhibits COX-1(84) and modifies COX
metabolite production to modulate platelet activation, and
inhibits the arachidonate-dependent synthesis of inflammatory
agents such as thromboxane B2, hydroxyheptadecatrienoate
and 12-hydroxyeicosatetraenoate(83). Data from molecular
modelling studies performed by in silico docking show
that resveratrol forms stable complexes in platelet COX-1
channels(83).
Resveratrol effects and in vivo relevance
Resveratrol at concentrations of up to 100mM is used in many
cell-culture studies(47); the molecular mechanisms obtained
with such concentrations may not easily extend to understand-
ing the effects of dietary resveratrol. It is unlikely that such
high plasma concentrations of resveratrol are achieved,
either by drinking red wine or by consuming resveratrol-
containing food. However, high doses of resveratrol are well
tolerated by animals(44) and by humans(85). The low toxicity
of resveratrol favours its use as a nutraceutical (to reach
higher in vivo concentrations).
As much as 70 % of orally ingested resveratrol can be
absorbed. However, the bioavailability of unchanged resvera-
trol is very low, due to rapid and extensive metabolism(85).
The plasma concentration and the half-life of resveratrol
metabolites are much greater than those of resveratrol(44),
indicating higher systemic exposure to the modified form
than to unchanged resveratrol. It is possible that part of the
in vivo effects of resveratrol can be attributed to its
metabolites.
Quercetin
Quercetin is a polyphenol that occurs in abundance in plants
and in the diet, and belongs to the flavonoid subclass that is
identified by their ketone group(7). The main source of quer-
cetin is black elderberry, but significant quantities are also
found in cocoa, Mexican oregano, capers and cloves while
smaller concentrations occur in nuts, onions, shallot, cran-
berry, apple and red wine. Quercetin, present in foods as
quercetin glycosides, represents 60–75 % of the total dietary
flavonols plus flavone intake(86).
Quercetin and oxidative stress
Quercetin scavenges free radicals in vitro and has epidemiolo-
gical correlates. Quercetin is a potent scavenger of superoxide
anion and peroxynitrite, inhibits superoxide anion generation
by suppressing xanthine oxidase activity(87) and inhibits the
mitochondrial NADH/NADþ system(88). Important is the find-
ing that the hydroxyl groups of quercetin contribute to the
generation of intracellular superoxide, leading to the inhi-
bition of cell proliferation and the induction of apoptosis in
leukaemia cells(89).
Quercetin and vasodilation
Quercetin causes endothelium-dependent vasodilation
through the production of NO(86,90) probably by increasing
eNOS phosphorylation at 5mM(91). Additionally, 50mM-
quercetin is proposed to also increase NO release by causing
a hyperpolarisation-dependent capacitative Ca2þ entry in iso-
lated cultured endothelial cells(92). These effects result in
endothelium-dependent vasodilatation that is inhibited by
eNOS inhibitors and charybdotoxin, thus demonstrating that
the quercetin effect is dependent on both the NO/cyclic gua-
nylyl monophosphate pathway and EDHF(91). Similar to the
effects of resveratrol, quercetin, at a physiologically relevant
concentration of 0·1mM, also increases eNOS mRNA
expression in HUVEC(66). Additionally, quercetin enhance-
ment of cyclic guanylyl monophosphate-dependent relaxation
in porcine isolated coronary arteries is insensitive to phospho-
diesterase 5 inhibition. Quercetin reduces the development of
glyceryl trinitrate-induced tolerance in vitro in porcine
arteries; these findings can benefit patients with angina
pectoris and await confirmation in humans(93).
Other studies report that quercetin treatment (100mM) sup-
presses eNOS activity in bovine aortic endothelial cells as a
result of decreased eNOS phosphorylation(94). This effect is
Polyphenols and cardiovascular protection 1537
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114512003406
Downloaded from https://www.cambridge.org/core. IP address: 130.79.37.237, on 12 Jun 2018 at 06:59:22, subject to the Cambridge Core terms of use, available at
associated with an in vitro disruption of mitotic microtubule
polymerisation and an in vivo inhibition of angiogenesis, as
quercetin inhibits vascular endothelial growth factor-induced
endothelial cell function and angiogenesis through the inhi-
bition of ERK1/2 (extracellular signal-regulated kinase 1/2)
phosphorylation(95).
Quercetin and vasoconstriction
As with resveratrol, quercetin decreases H2O2-induced
endothelin-1 mRNA expression and reduces endothelin-1
release in HUVEC(66). Moreover, quercetin, at 1mM and more
so at 10mM, prevents endothelin-1-induced endothelial dys-
function and NADPH oxidase subunit p47phox overexpres-
sion by inhibiting protein kinase C(96).
The detailed effects of quercetin on the renin–angiotensin
system are not known. Treatment of Dahl salt-sensitive hyper-
tensive rats with quercetin (10 mg/kg) for 4 weeks reduces
blood pressure along with decreases in angiotensin II type 1
receptor mRNA, suggesting modulation of renal function by
quercetin(97). It should be noted that quercetin fails to
modify ACE activity either in vitro using rat kidney mem-
branes(98) or in vivo after administration to rats(99), suggesting
that the antihypertensive effect of quercetin may be unrelated
to actions on the renin–angiotensin system.
Quercetin and inflammation
Although various mechanisms are involved in the anti-
inflammatory properties of quercetin, it mainly targets signal-
ling pathways related to NF-kB activation. Thus, quercetin
(10mM) decreases mRNA and protein levels of TNFa, IL-1b,
IL-6, macrophage inflammatory protein-1a and inducible NO
synthase in several in vitro and in vivo studies(100). Quercetin
has pleiotropic effects in apoE-KO mice related to the
reduction of pro-inflammatory markers (isoprostane, leuko-
triene B4 and P-selectin) and the enhancement of anti-
inflammatory indicators (eNOS and haem oxygenase-1
expression)(101), suggesting that quercetin at a dose of
1·3 mg/d could delay the atherosclerotic process through its
anti-inflammatory properties. Also, adiponectin mRNA levels
are enhanced in adipose tissue from rats receiving quercetin
fed high-fat diets(102). High concentrations of quercetin
(40mM) suppress the Akt phosphorylation and transactivation
of nuclear factor activator protein-1 and NF-kB, resulting in an
inhibition of the TNF-a-induced up-regulation of cell
migration(103). In addition, by reducing the production of
pro-inflammatory cytokines and enzymes, quercetin (50mM)
inhibits mouse dendritic cell activation, suggesting that
quercetin could be a potent immunosuppressive agent(104).
However, contradictory results have been described in
human subjects as no effects on the inflammatory profile
were detected in females receiving a 12-week supplemen-
tation with quercetin (0·5–1 g/d)(105). Dietary supplementation
of quercetin in combination with vitamin C for 4 weeks does
not change plasma biomarkers of inflammation (TNF-a, IL-1b,
IL-6 and C-reactive protein) and the disease severity of
rheumatoid arthritis patients(106).
Quercetin and platelet function
Platelet aggregation contributes to both the development of
atherosclerosis and to acute platelet thrombus formation,
followed by embolisation of stenosed arteries. Quercetin
impairs in vitro platelet aggregation induced by thrombin by
interfering with Ca2þ mobilisation and serotonin secretion(107),
and inhibiting platelet kinases such as phosphatidylinositol-3-
kinsase and Src kinases(108). These results were obtained with
concentrations that exceed those attained after standard con-
sumption of flavonoid-rich foods. Quercetin inhibits platelet
aggregation independently of the agonist used (arachidonic
acid or ADP)(83). Quercetin inhibits platelet activation through
the blockade of activity of the proto-oncogene tyrosine-
protein kinase Fyn and the tyrosine phosphorylation of
spleen tyrosine kinase (Syk) and phospholipase C gamma 2
(PLCg2) following quercetin internalisation in platelets(109).
Limitations of the use of quercetin
Quercetin is absorbed through the gastrointestinal tract
and rapidly metabolised by methylation and conjugation
with glucuronic acid and/or sulphate in enterocytes and in
the liver(110,111). Once conjugated, quercetin is present in
plasma after repeated daily dosage(112), and, paradoxically,
although the plasma concentrations of free quercetin are
very low, it can occur in relatively high concentrations in sev-
eral tissues indicating that in situ deconjugation of quercetin
can occur(113).
Delphinidin
Anthocyanins are the largest group of water-soluble pigments in
the plant kingdom and are responsible for most of the red, blue
and purple colours of fruits, vegetables, flowers and other plant
tissues or products(2). The six anthocyanins commonly found in
plants are classified according to the number and position of
hydroxyl and methoxyl groups on the flavan nucleus, and are
named pelargonidin, cyanidin, delphinidin, peonidin, petuni-
din and malvidin. The daily intake of anthocyanins in humans
is approximately 180–215 mg/d in the USA(3), with the major
sources of anthocyanins being blueberries, cherries, raspber-
ries, strawberries, black currants, purple grapes and red wine;
a 100 g serving of berries provides up to 500 mg anthocyanins.
Various metabolites are formed during the metabolism of
anthocyanins and anthocyanidins and include glucuronides
and methylated and sulphated derivatives of anthocyanins(114).
Among the different classes of polyphenolic compounds
present in red wine, anthocyanins and oligomeric condensed
tannins exhibit pharmacological profiles comparable with total
red wine extracts in terms of endothelial-dependent NO-
mediated vasodilatation(115). Of the different anthocyanins
identified in wine, only delphinidin causes endothelium-
dependent relaxation, although it is slightly less potent than
total red wine extract(115).
Delphinidin and oxidative stress
Delphinidin possesses antioxidant effects in a wide range
of chemical oxidation systems by virtue of two hydroxyl
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groups on the phenyl ring(116), and among the anthocyanins,
delphinidin has the greatest in vitro potency against superox-
ide anions and peroxynitrite(117). Since this study was
performed at neutral pH, it is not clear whether this potency
is maintained in vivo. Its ability to scavenge ROS protects
endothelial cells from LDL-induced lipid oxidation, although
it is not clear whether the effects of delphinidin in quenching
ROS are by direct actions on LDL. Nevertheless, delphinidin
(25–200mM) restores SOD activity to a similar extent to that
produced by vitamin C, suggesting that delphinidin maintains
endothelial cell function by preserving endogenous anti-
oxidants and by attenuating lipid peroxidation(118). Treatment
of CCl4-intoxicated mice with delphinidin (25 mg/kg, once
daily for 2 weeks) decreases oxidative stress in the liver as
reflected by the recovery of GPx activity and the ratio reduced
glutathione:oxidised glutathione. These antioxidant effects of
delphinidin are associated with antifibrotic activity, indicating
that delphinidin possesses a tissue-regenerative capability(119).
Cytotoxic effects of delphinidin (100mM for 24 h) in metastatic
cells (but not in cells originating from a primary tumour site)
are related to cellular free radical accumulation, inhibition of
glutathione reductase and depletion of glutathione, suggesting
that delphinidin could be used as a sensitising agent in meta-
static therapy(120).
Delphinidin and vasodilation
Delphinidin stimulates NO production independently of its
antioxidant property(20). Delphinidin activates NO release by
increasing intracellular Ca2þ concentrations through the
release from intracellular stores and the entry from the extra-
cellular space. In bovine aortic endothelial cells, delphinidin-
induced increases in intracellular Ca2þ are accompanied by
tyrosine phosphorylation of several intracellular proteins(121).
Acute treatment with delphinidin (10 min) enhances NO
release and eNOS phosphorylation at Ser1177(26).
The only study of the angiogenic properties of low doses of
delphinidin (0·06 mg/kg per d) reports no effects on the recov-
ery of blood flow in ischaemic hindlimbs, while higher doses
of delphinidin (0·6 mg/kg per d) have anti-angiogenic effects
as characterised by impaired blood flow and decreased
vascular density in the ischaemic leg of rats(122). These results
are similar to those obtained with the whole extracts from red
wine, suggesting that delphinidin could play an important role
in the anti-angiogenic effect of red wine.
By targeting STAT1 (a nuclear transcriptional factor of the
signal transducers and activators family and which has a
critical role in cardiomyocyte apoptosis), delphinidin (more
potently than quercetin) provides protection against
ischaemia–reperfusion injury in isolated cardiomyocytes and
in the Langerdoff-perfused rat heart when used at 10mM 2 h
before the onset of the ischaemic insult(123).
Delphinidin and vasoconstriction
Delphinidin reduces both mRNA and protein levels of
endothelin-1 in cultured HUVEC(124). While resveratrol and
quercetin (30mM) reduce endothelin-1 production by
only 20 %, similar concentrations of delphinidin lower
endothelin-1 production by approximately 75 %(125). Although
the inhibition of purified ACE by oligomeric procyanidins
(mainly oligomeric epicatechins) is well established(126),
the effects of delphinidin-3-O-sambubioside on ACE have
only been recently reported. This compound inhibits ACE by
competing with the active site of the enzyme, with an half-
maximal inhibitory concentration value similar to that
obtained with quercetin(127).
Delphinidin and inflammation
Several in vitro studies report that delphinidin interacts
directly with kinases; however, it is not established whether
delphinidin also has similar effects in vivo. Delphinidin
(5–20mM) suppresses COX-2 promoter activity and COX-2
expression in mouse epidermal cells by inhibiting activator
protein-1 and NF-kB pathways; these effects result from the
direct binding of delphinidin to the ATP-binding site in the
kinase domain of mitogen-activated protein kinase kinase 4
and to the ATP-binding site of the catalytic domain of
phosphatidylinositol-3-kinsase(128). Delphinidin (10–40mM)
inhibits phosphorylations of c-Jun N-terminal kinases, p38
mitogen-activated protein kinase, Akt and ERK as well as
Fyn kinase in mouse epidermal cells, and directly binds with
Fyn kinase in a non-competitive manner with ATP(129).
Additionally, delphinidin also inhibits a broad spectrum
of receptor tyrosine kinases of the epidermal growth factor
receptor B (ErbB) and vascular endothelial growth factor
receptor families in both cell-free assays and intact cell
systems(130). Other enzymes potentially playing a role in
inflammation are also inhibited by delphinidin: for example,
a mixed competitive and non-competitive phospholipase A2
inhibition has been described for delphinidin in a cell-free
assay(131), while delphinidin also weakly inhibits proteasome
activity(132). These data highlight the ability of delphinidin to
interfere with pro-inflammatory pathways, although no evi-
dence of in vivo effects on these enzyme systems is available.
Delphinidin and platelet function
Although aqueous residues containing the anthocyanic frac-
tion from red wine suppressed ADP-induced platelet aggrega-
tion(133), delphinidin was unable to inhibit collagen-induced
platelet aggregation in vitro (133). Delphinidin containing
fractions from purple grapes inhibits whole-blood aggrega-
tion, suggesting a potential mechanism for the beneficial
effects of polyphenols on the suppression of platelet-mediated
thrombosis(134).
Limitations on the use of delphinidin
Although abundant in the diet, anthocyanins, in general, and
delphinidin in particular, are either poorly absorbed or not
absorbed at all. One consequence of the poor bioavailability
of anthocyanins is that many effects observed in vitro (e.g.
inhibition of COX-2) are unlikely to occur in vivo. The
measurement in plasma or urine of the original anthocyanins
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and their conjugated metabolites (glucuronidated and
sulphated anthocyanins) indicates their very low bioavailabil-
ity(7,135). In addition, intestinal microflora play an important
role in the metabolism of anthocyanins(136). Clearly, additional
in vivo studies on the effects of delphinidin are needed to
establish the beneficial effects of concentrations used in
in vitro studies, which generally tend to be higher than
those attained physiologically.
Molecular targets of polyphenols
The ability of polyphenols to target transcriptional networks
that modulate gene expression favouring NO production,
anti-inflammatory mediators and energy expenses provides
an attractive pharmacological approach to treat cardiovascular
and metabolic diseases (Fig. 3). Some molecular targets of
polyphenols are discussed below.
AMP-activated protein kinase
AMP-activated protein kinase (AMPK) is a Ser/Thr protein
kinase involved in ATP production in mammalian cells(137).
The AMPK cascade may have an important role in preventing
diseases since AMPK inhibits fat accumulation, reduces
cholesterol synthesis and modulates inflammatory cytokines.
Polyphenols found in natural products can target and activate
AMPK leading to numerous beneficial effects in cardiovascular
and metabolic diseases, as shown by the finding that
activation of AMPK by resveratrol is SIRT1-independent(138)
(see below). By increasing AMPK phosphorylation, resveratrol
prevents the development of hyperlipidaemia and athero-
sclerosis in diabetic mice(139). These effects may be related
to reduced fat accumulation(140), enhanced glucose transpor-
ter GLUT4 translocation and increases in glucose uptake by
diabetic rat cardiomyocytes(141). Resveratrol increases physical
endurance and mitochondrial biogenesis as revealed by
increases in the expressions of PPARg coactivator (PGC)-1a,
PGC-1b, oestrogen-related receptor a and nuclear respiratory
factor (NRF) in AMPK-deficient mice, leading to improved glu-
cose homeostasis through mechanisms dependent on AMPK
activation(140).
Quercetin also activates the AMP–AMPK pathway via down-
regulation of protein phosphatase 2C in the brains of old
mice fed a cholesterol-rich diet, indicating that quercetin
enhances the resistance of neurons to age-related diseases
via AMPK pathway activation(142). Furthermore, quercetin
inhibits adipocyte 3T3-L1 differentiation by decreasing
adipogenic transcription factors such as PPARg and CCAAT/
enhancer-binding protein via the phosphorylation of mito-
gen-activated protein kinase, suggesting that quercetin can
regulate the adipocyte life cycle(143). Dietary bilberry extracts
rich in anthocyanidins ameliorate hyperglycaemia and insulin
sensitivity in diabetic mice by activating AMPK in the adipose
tissue, skeletal muscle and liver(144).
Sirtuin 1
Polyphenols such as resveratrol activate a NADþ-dependent
protein deacetylase, silent information regulator orthologue 1
(SIRT1)(145), which regulates a variety of cellular functions
such as genome maintenance, longevity and metab-
olism(146,147). Resveratrol increases the lifespan in animals
partially via the stimulation of SIRT1, in a manner similar to
energy restriction(148). Resveratrol augments exercise endur-
ance in mice through the deacetylation of PGC-1a (a mito-
chondrial biogenesis factor) by SIRT1 to stimulate
mitochondrial function in muscle and brown adipose
tissue(149). The pleiotropic effects of resveratrol, which occur
by the activation of SIRT1, could protect animals from obesity
and diabetes by shifting the energy balance towards energy
consumption rather than storage(149).
Small-interfering RNA against SOD2 or SIRT1 reduce the
cell-protective effects of resveratrol(51). Although a recent
study using cell-free assays questions the ability of resveratrol
to activate SIRT1 directly(150), it is highly likely that resveratrol
(or its metabolites) can promote SIRT1 activation in vivo.
Moreover, resveratrol also enhances the expression levels of
SIRT1. In an attempt to address this, Li’s group reported that
inhibition of SIRT1 activity with sirtinol or knockdown of
SIRT1 expression with siRNA both reduced the effects of
resveratrol on SOD1, SOD2 and GPx1, but not those on SOD3
and catalase(52). This finding is consistent with the findings
that resveratrol up-regulates SOD2 in C2C12 myoblasts in a
SIRT1-dependent manner(51).
Of note is the report that SIRT1 also activates the
transcriptional activity of PGC-1a, and subsequently induces
mitochondrial biogenesis and lipolysis, and so inhibits the gen-
eration of ROS from the mitochondria(151). The activation of
SIRT1 is related to both lipid and glucose homeostasis; thus,
SIRT1 inhibits adipogenesis, reduces fat storage in adipose
tissue(152) and increases insulin secretion and sensitivity(153).
Resveratrol stimulates eNOS activity by SIRT1 activation and
eNOS deacetylation(154). For example, resveratrol increases
mitochondrial mass and up-regulates eNOS by activating
SIRT1 in human coronary arterial endothelial cells, where
the ability of resveratrol to induce mitochondrial biogenesis
is NO-dependent(155). Likewise, SIRT1 activation by other
stimuli such as laminar flow and statin treatment also increases
eNOS activity and NO production(156). Thus, the interaction
between SIRT1 and eNOS contributes to the cardiovascular
beneficial effects of resveratrol. The multifaceted molecular
mechanisms for the cardiovascular benefits of resveratrol are
summarised in Fig. 4.
In a similar manner, treating mice with quercetin enhances
mRNA expression of PGC-1a and SIRT1 to increase both
maximal endurance capacity and running activity(157). The
possibility of targeting SIRT1 by polyphenols, and thereby
co-affecting PGC-1a signalling, makes endothelial mitochon-
dria important in CVD and metabolic disorders.
Oestrogen receptor a
Due to the structural similarities with diethylstilbestrol (a
synthetic oestrogen), resveratrol has been proposed to activate
the ER. Resveratrol binds to and activates gene transcription
via the ER in oestrogen-sensitive tissues and cell lines(158).
Of interest, resveratrol binds ERb with a lower affinity than
R. Andriantsitohaina et al.1540
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114512003406
Downloaded from https://www.cambridge.org/core. IP address: 130.79.37.237, on 12 Jun 2018 at 06:59:22, subject to the Cambridge Core terms of use, available at
at ERa(159). Owing to its properties as an agonist for the ER,
resveratrol is able to regulate the transcription of oestrogen-
responsive target genes, and possibly has cancer chemopre-
ventive effects(160). Activation of ER is a key step in the effects
of resveratrol on glucose uptake by muscles(161). At the
molecular level, resveratrol rapidly activates ERa in caveolae,
leading to eNOS activation by the stimulation of G-protein Ga,
caveolin-1 (Cav-1), Src and ERK1/2K; siRNA knockdown of
ERa, but not ERb, or the presence of ER antagonists inhibits
the rapid eNOS activation by resveratrol(68).
As described for resveratrol, quercetin is also able to reduce
oestrogen-sensitive tumour growth in mouse models by
directly acting on ER(162) and by down-regulating cytoplasmic
ER levels and promotion of a tighter nuclear association of
the ER(163). Quercetin exhibits a similar potency of both ER
subtypes(164) and stimulates the expression of the proto-
oncogene c-fos through ERa activation(165).
Recent data suggest that delphinidin interacts directly with
the activator site of ERa, leading to the activation of eNOS.
Thus, the ability of delphinidin (and of total polyphenolic
extract from red wine) to induce NO production and endo-
thelium-dependent vasorelaxation data is lost in ERa-deficient
mice or after using siRNA for this receptor(26). Silencing
the effects of ERa completely prevents delphinidin
activation of Src, ERK1/2 and eNOS, while binding assay
and docking experiments indicate a direct interaction
between delphinidin and the ERa activator site. Oral
administration of total polyphenolic extracts from red wine
increases the sensitivity of endothelium-dependent relaxation
to acetylcholine and is associated with increased NO pro-
duction and decreased superoxide anions in control mice
but absent in ERa-deficient mice(26).
Interaction between molecular targets of polyphenols
It is likely that there is an intracellular crosstalk of signalling
cascades activated by molecular targets of polyphenols. For
example, resveratrol modulates tumour cell proliferation and
protein translation via SIRT1-dependent AMPK activation in
ER-positive breast cancer cells, highlighting the interactions
of ER, SIRT1 and AMPK(166). Resveratrol induces deacetylation
of PGC-1a mediated by SIRT1 and phosphorylation of
AMPK in the liver to promote fatty acid oxidation and inhibit
lipogenesis(167). It is likely that SIRT1 may be upstream of
AMPK, since SIRT1 activation increases AMPK activity(168),
probably by SIRT1 deacetylation/activation of the upstream
AMPK kinase liver kinase B1 (LKB1)(169). Finally, eNOS acety-
lation is higher in AMPKa2-deficient mice, suggesting
that AMPK phosphorylation of eNOS is required for SIRT1
deacetylation of eNOS(156). These findings suggest that the
improvement of cell function produced by the polyphenols
resveratrol, quercetin and delphinidin occurs by the activation
of several signalling mechanisms in addition to the transcrip-
tional and post-translational effects.
Resveratrol
SIRT1 Nrf2 ?
?
?
?
PGC-1α
GCH1
SOD2 GPx1
Cat.
NQO1
HO-1
GCLC Trx-1SOD1
Mito.
biogenesis
eNOS
uncouplingNOX
ROS generation ROS detoxification
Oxidative stress
Fig. 4. Resveratrol reduces oxidative stress by decreasing reactive oxygen species (ROS) production from NADPH oxidases (NOX), uncoupled endothelial NO
synthase (eNOS, by up-regulating GTP cyclohydrolase 1, GCH1) and mitochondria (by stimulating mitochondrial (Mito.) biogenesis). In addition, resveratrol
enhances the expression of antioxidant enzymes, such as superoxide dismutases (SOD1–3), catalase (Cat.), glutathione peroxidase 1 (GPx1), NAD(P)H:quinone
oxidoreductase 1 (NQO1), g-glutamylcysteine synthetase (glutamate cysteine ligase catalytic subunit, GCLC), haem oxygenase-1 (HO-1) and thioredoxin-1
(Trx-1). SIRT1, sirtuin 1; PGC-1a, PPARg coactivator 1-a; Nrf2, nuclear factor E2-related factor-2. (A colour version of this figure can be found online at
http://www.journals.cambridge.org/bjn)
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Polyphenols and CVD
Cardiovascular mortality exceeds cancers as the leading cause
of death in the world. CVD include CHD, stroke, hyper-
tension, peripheral artery disease and heart failure. The
major causes of CVD are tobacco use, physical inactivity and
hyperenergetic diets.
Hypertension
Hypertension causes modifications of the vascular walls that
lead to hypertensive cardiomyopathy and heart failure(170).
Changes in the mechanical properties of arteries affect vascu-
lar resistance by altering the pressure–lumen diameter
relationship of small arteries(74). Part of the cardioprotective
actions of polyphenols is by lowering blood pressure. How-
ever, contradictory data are available: for instance, an antihy-
pertensive effect of resveratrol was reported in partially
nephrectomised rats(171), while in double transgenic rats har-
bouring human renin and angiotensinogen genes, resveratrol
reduces blood pressure, ameliorates cardiac hypertrophy
and prevents angiotensin II-induced mortality, probably by
increasing mitochondrial biogenesis and SIRT1 activity(172).
Resveratrol probably suppresses angiotensin II type 1 receptor
expression through SIRT1 activation, suggesting that the inhi-
bition of the renin–angiotensin system may contribute, at least
in part, to the resveratrol-induced cardiprotective effects(33).
Other studies report that resveratrol does not affect established
hypertension in SHR(173), although it attenuates the compli-
ance of arteries from SHR without changes in wall stiffness
by reducing eutrophic remodelling(174).
Chronic treatment with quercetin (10 mg/kg) reduces systo-
lic blood pressure and significantly reduces left ventricular and
renal hypertrophy in SHR(175), hypertension induced by the
inhibition of NOS(86) and in deoxycorticosterone acetate-salt
hypertensive rats(176). It appears that quercetin is effective in
all animal models of hypertension studied, and acts indepen-
dently of the status of renin–angiotensin system, oxidative
stress, NO, etc.(86).
Short-term oral administration of polyphenols from red
wine (a rich source of delphinidin) decreases blood pressure
in normotensive rats. This haemodynamic effect was associ-
ated with an enhanced endothelium-dependent relaxation
and an induction of gene expression within the arterial wall,
which together maintain unchanged agonist-induced contrac-
tility(177). Polyphenols from red wine reduce blood pressure
elevations caused by chronic inhibition of NOS, attenuate
end-organ damage such as myocardial fibrosis and aortic
thickening, and decrease protein synthesis in the heart
and aorta(178,179). Polyphenols also prevent endothelium-
dysfunction by increasing eNOS activity, moderately
enhancing eNOS expression and reducing oxidative stress in
the left ventricle and aorta. Endothelial dysfunction associated
with excessive NADPH oxidase-dependent vascular formation
of ROS in angiotensin II-induced hypertension is prevented by
polyphenols(31). Thus, polyphenols from red wine reduce
hypertension by modulating the NO and ROS balance in the
cardiovascular system.
Stroke
Cerebral ischaemia is caused by reduced cerebral blood flow.
Stroke involves the interaction of neurons, glia, vascular cells
and matrix components, all of which participate in the
mechanisms of tissue injury and repair. The severe reduction
of cerebral blood flow initiates a series of pathophysiological
mechanisms such as impaired energy metabolism, loss of ionic
homeostasis, excessive release of excitatory amino acids
(mainly aspartate and glutamate) and increased oxidative
stress. All these processes lead to brain tissue damage and
cell death.
Resveratrol reduces infarct volume in various experimental
models of stroke(180). The mechanisms involved in neuropro-
tection are largely by the inhibition of lipid oxidation pro-
cesses. More recent data indicate that resveratrol significantly
restores ATP content and the activity of mitochondrial respir-
atory complexes in a model of transient rat middle cerebral
artery occlusion by decreasing apoptosis, mitochondrial lipid
peroxidation, brain infarct volume and oedema(181). In the
stroke model, resveratrol improves neurological function by
reducing the release of excitatory neurotransmitters (gluta-
mate and aspartate), and increases inhibitory neurotransmitter
release (g-amino-n-butyric acid and glycine)(182). It is likely
that these effects are mediated through the activation of oes-
trogen and N-methyl-D-aspartate receptors(183) or the SIRT1
pathway(184). Resveratrol administration also induces angio-
genesis in the cortical area of mice exposed to middle cerebral
artery ischaemia(185). These findings highlight the ability of
resveratrol to preserve ischaemic neurovascular units in the
treatment of ischaemic stroke.
Liposomal preparations of quercetin that enhance neuropro-
tective capacity reduce cerebral damage provoked by cerebral
ischaemia(186). Repeated treatment with quercetin for 15 d
before ischaemic surgery in gerbils reduces lipid peroxidation,
Vasodilatation Vasoconstriction
Pro-inflammatory response
Smooth muscle cell
ROS
ROS
AT1
NADPH
oxidase
PI3K/Akt
 P
EDHFEDCF
Endothelial
cell
NO
COX
Platelet activation
Endothelial dysfunction
Improvement of vascular health
Polyphenols
Fig. 5. The protective effect of polyphenols on blood vessels is due to their
ability to act on endothelial cells to increase the formation of the vasoprotec-
tive factors NO and endothelium-derived hyperpolarising factor and reduce
the endothelial formation of cyclo-oxygenase (COX)-derived vasocontracting
factors, and also on vascular smooth muscle cells to reduce oxidative stress,
in part, by decreasing the expression of NADPH oxidase and, possibly, also
the angiotensin 1 receptor. ROS, reactive oxygen species; PI3K/AKT, phos-
phatidylinositol-3-kinsase/Akt; EDCF, endothelium-derived contracting factor;
EDHF, endothelium-derived hyperpolarising factor; AT1, angiotensin type 1
receptor. (A colour version of this figure can be found online at
http://www.journals.cambridge.org/bjn)
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suggesting that early administration of quercetin could offer
protection of neuronal units during cerebral ischaemia(187).
Feeding rats with diets enriched in anthocyanins from
blueberries provides neuroprotection after stroke induced
by ligation of the left common carotid artery independently of
their ability to scavenge oxygen radicals(188). An anthocyanin-
rich extract from red wine reduces injury induced by cerebral
ischaemia in rats, and protects from ischaemia-induced
excitotoxicity (by reducing the release of the excita-
tory neurotransmitters glutamate and aspartate), energy failure
(by increasing glucose concentrations) and oxidative stress
(by increasing levels of ascorbic and uric acids)(189). Long-
term administration of polyphenols partially restores cerebral
blood flow during cerebral artery occlusion and improves
flow during reperfusion in the cortex, as measured by
increased diameters of the arteries of the cerebral tree, while
also causing differential expression of proteins involved in
neuroprotection, maintenance of neuronal integrity, oxidative
stress, energy metabolism and inflammation (such as neurofi-
lament medium polypeptide (NF-M) or TOAD-64)(190). These
experimental data indicate the beneficial effects of polyphe-
nols in stroke protection, or in treatment during different
phases of the disease.
Polyphenols and metabolic diseases
Resveratrol extends the lifespan in mice fed a high-fat diet by
reducing fat accumulation and improving glucose tolerance
and insulin sensitivity(167). Hypercholesterolaemic swines
receiving resveratrol (100 mg/kg per d for 1 month) have
reduced BMI, total cholesterol, LDL, blood glucose levels
and systolic blood pressure(191), while in Zucker obese rats,
resveratrol improves inflammation (by increasing adiponectin
and reducing TNF-a production in the visceral adipose tissue)
and reduces plasma concentrations of TAG, total cholesterol,
NEFA, insulin and leptin(192). At a molecular level, resveratrol
inhibits preadipocyte proliferation and adipogenic differen-
tiation in a SIRT1-dependent manner(193). In human adipo-
cytes, resveratrol stimulates basal and insulin-stimulated
glucose uptake, while de novo lipogenesis is inhibited in
parallel with a down-regulation of lipogenic gene expression.
Furthermore, resveratrol influences the secretory profile of
human preadipocytes in a way that can positively interfere
with the development of obesity-associated co-morbidities(193).
Other studies implicate ERa in resveratrol-stimulated, insulin-
dependent and -independent glucose uptake(161).
Quercetin (2 or 10 mg/kg) improves dyslipidaemia, hyper-
tension and hyperinsulinaemia in obese Zucker rats, but
only the higher dose evokes the anti-inflammatory effects in
visceral adipose tissue(194). However, quercetin is unable to
improve insulin sensitivity in SHR(175). Comparing the same
doses of resveratrol and delphinidin (2·1 mg/kg) in a rat
model of the metabolic syndrome shows that only delphinidin
prevents insulin resistance without reducing high blood
pressure(195).
There are beneficial effects of dietary supplementation of
red wine polyphenol extracts on obesity-associated alterations
with respect to changes in metabolic disturbances and
cardiovascular function in Zucker fatty rats(196). These poly-
phenols improve glucose metabolism by reducing plasma
glucose and fructosamine in Zucker fatty rats. Moreover,
polyphenols reduce circulating TAG, total cholesterol as well
as LDL-cholesterol in Zucker fatty rats; echocardiography
measurements indicate improved cardiac performance asso-
ciated with decreased peripheral arterial resistance(196). Poly-
phenol extracts improve vasodilation by enhancing eNOS
activity and reducing superoxide anion release via decreased
expression of the NADPH oxidase membrane subunit
Nox-1(196), suggesting that polyphenol consumption may be
helpful in reducing obesity-associated metabolic disorders.
Conclusions
Several sources of polyphenols including red wines, grape
juices and green teas have the potential to improve vascular
health, for example, by stimulating the formation of vasopro-
tective factors such as NO and EDHF to promote vasodilata-
tion and prevent platelet activation. Polyphenols can also
improve vascular smooth muscle function, by reducing the
excessive vascular oxidative stress of pathological blood
vessels. The antioxidant effect probably reflects changes in
the expression levels of antioxidant and pro-oxidant enzymes.
Polyphenol treatments are associated with a reduced
expression of NADPH oxidase, a vascular source of superox-
ide anions, and a reduced angiotensin system, a strong activa-
tor of NADPH oxidase. The reduced oxidative stress will
prevent the degradation of NO by superoxide anions and
also prevent vasoconstriction and pro-inflammatory responses
(Fig. 5). Thus, actions of polyphenols on endothelial and
smooth muscle cells can promote vascular health.
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